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Abstract  Herpes  zoster  ophthalmicus  (HZO)  may  cause  a  variety  of  ocular  conditions  includ-
ing: dermatitis,  corneal  pseudo-dendrites,  uveitis,  retinitis,  and  cranial  nerve  palsies.  Cranial
nerve palsies  caused  by  herpes  zoster  (HZ)  are  relatively  uncommon  clinical  ﬁndings.  Previous
case reports  have  looked  at  this  relationship,  but  the  overall  case  studies  are  few.  Other  causes
of nerve  palsies  typically  need  to  be  ruled  out  ﬁrst  with  neuro-imaging  and  blood  evaluations.
However,  when  HZ  is  conﬁrmed,  treatment  with  oral  antiviral  therapy  and/or  oral  corticoste-
roids along  with  monitoring  the  individual  usually  results  in  a  self-limiting  ophthalmoplegia  that
improves on  its  own  over  several  months.  We  report  a  case  of  cranial  nerve  III  palsy  resulting
from HZO.
©  2012  Spanish  General  Council  of  Optometry.  Published  by  Elsevier  España,  S.L.  All  rights
reserved.
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Herpes  zoster  oftálmico-parálisis  inducida  del  nervio  oculomotor
Resumen  El  herpes  zoster  oftálmico  (HZO)  puede  causar  una  serie  de  alteraciones  oculares
que incluyen:  dermatitis,  pseudo-dendritas  corneales,  uveítis,  retinitis,  y  parálisis  de  los  nervios
craneales.  Las  parálisis  de  los  nervios  craneales  causadas  por  herpes  zoster  son  hallazgos  rela-
tivamente  infrecuentes.  Los  informes  de  casos  previos  han  contemplado  esta  relación,  pero  los
estudios  de  casos  globales  son  escasos.  Normalmente  deben  descartarse  primeramente  otras
causas de  parálisis  nerviosas  mediante  neuro-imagen  y  pruebas  sanguíneas.  Sin  embargo,  al  con-
ﬁrmarse el  herpes  zoster,  el  tratamiento  con  terapia  antivírica  oral  y/o  corticosteroides  orales,
junto con  la  supervisión  del  paciente,  deriva  normalmente  en  una  oftalmoplejía  auto-limitante
que mejora  por  sí  misma  transcurridos  varios  meses.  Reportamos  el  caso  de  una  parálisis  del  III
r  HZOnervio craneal,  causada  po
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Introduction
HZO  is  a  reactivation  of  the  childhood  chicken  pox  virus
(varicella  zoster)  along  the  ophthalmic  division  of  the  5th
cranial  nerve  (CN  V1)  which  typically  reveals  itself  as  a  vesic-
ular  rash  or  dermatitis.2--4 Varicella  and  HZO  differ  only  in  the
location  they  occur  in  the  body,  not  in  mechanism  or  type  of
virus.  The  varicella  zoster  virus  (VZV)  typically  lies  latent  in
the  dorsal  root  ganglion  of  nerves  and,  if  reactivated,  trav-
els  down  the  associated  dermatome  of  the  nerve  involved.  If
VZV  affects  the  ophthalmic  division  of  cranial  nerve  V  then
it  is  termed  HZO.  If  it  affects  another  nerve  it  is  referred  to
as  shingles  or  just  generic  HZ.1--4 HZ  typically  affects  older
populations  of  individuals  who  were  exposed  to  VZV  as  a
child.  A  study  has  shown  that  over  90%  of  12-year  olds  were
seropositive  for  VZV  and  over  99%  of  adults  ≥40  years  old
were  seropositive  for  VZV  in  the  United  States.5 Severity  is
related  to  the  age  of  the  patient  with  older  patients  (≥60
years  old)  being  affected  much  more  severely  than  younger
patients.6 In  fact,  the  lifetime  risk  of  HZ  is  estimated  to  be
approximately  25%  in  the  general  population,  and  increases
to  50%  in  patients  more  than  85  years  old.5
HZO  occurs  in  20%  of  all  HZ  outbreaks.  Patients  typi-
cally  present  with  an  acute  onset  of  a  unilateral  vesicular
dermatitis  along  the  CN  V1 dermatome  which  respects  the
midline.  Pseudo-dendrites  of  the  cornea  are  fairly  common
and  one  has  a  higher  risk  of  ocular  complications  if  the
rash  spreads  to  involve  the  tip  of  the  nose,  also  known
as  a  positive  ‘‘Hutchinson’s  sign.’’  This  signals  nasocil-
iary  nerve  involvement  (Fig.  1A  and  B).2--4 Rarer  ocular
complications  such  as  iridocyclitis,  glaucoma,  retinitis,  and
cranial  nerve  palsies  may  also  occur  in  Zoster  patients.2--4
The  following  case  report  discusses  a  patient  who  developed
a  complete  oculomotor  nerve  (CN  III)  palsy  with  pupil-
lary  involvement  after  being  diagnosed  with  HZO  one  week
prior.
Case report
An  84-year-old  American-American  female  presented  to  the
Urgent  Eye  Care  Service  at  the  Illinois  Eye  Institute  in
Chicago,  IL  as  a  referral  for  an  ocular  examination  follow-
ing  a  prior  diagnosis  of  HZO.  The  patient  had  been  released
from  a  local  hospital  the  previous  day.  She  presented  with
a  complaint  of  soreness  around  her  upper  left  eyelid  and
concomitant  blurry  vision  in  her  left  eye  (OS).  The  patient
denied  diplopia  and  decrease  in  vision  in  her  right  eye
(OD).  Her  ocular  history  was  positive  for  cataracts  in  both
eyes  (OU),  and  she  was  scheduled  for  cataract  extraction
in  1--2  months.  The  patient’s  medical  history  was  posi-
tive  for  hypertension,  kidney  problems,  and  a  history  of
breast  cancer.  She  reported  taking  carvedilol,  nifedipine,
furosemide,  and  a  potassium  pill  for  her  hypertension  and
kidney  issues.  The  patient  had  been  prescribed  oral  acy-
clovir  800  mg  5  times  per  day,  acetaminophen/codeine  as
needed  for  pain,  and  erythromycin  ointment  for  her  left
eye  by  the  on-call  physician  at  the  hospital  from  the  day
before.  She  reported  compliance  with  medications.  The
patient  reported  an  unremarkable  social  history  and  denied
any  drug  and/or  medical  allergies.  She  was  oriented  to  time,
place,  and  person.
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1Figures  1A  and  1B  Positive  Hutchinson’s  sign.
Entering  acuities  with  spectacle  correction  of
1.50  −  1.75  ×  110  OD,  +1.75  −  1.75  ×  080  OS  with  a
3.00  add  OU  were  20/50+  OD  and  20/60+  OS  with  no
mprovement  with  pinhole  OU.  The  patient’s  pupils  were
qual,  round,  and  reactive  to  light,  with  no  sign  of  an
fferent  pupillary  defect  (APD)  OU.  Ocular  motility  showed
ull  range  of  motion  with  no  pain  on  eye  movement  OU.
onfrontation  visual  ﬁelds  were  full-to-ﬁnger-count  OD,
ith  only  a  mild  superior  ﬁeld  defect  OS  secondary  to  her
tosis  and  mild  edema  of  the  upper  eyelid.
Anterior  segment  examination  revealed  clear  lids  and
ashes  OD,  but  upper  eyelid  ptosis  with  mild  edema  and
rusted-over  vesicles  were  evident  OS.  The  palpebral  and
ulbar  conjunctivae  were  white  and  quiet  OU.  Corneal
xamination  was  clear  OD,  but  pseudo-dendrites  were  noted
uperior  temporally  along  the  corneal  limbus  OS,  which
tained  with  sodium  ﬂuorescein  (NaFl)  but  did  not  with
issamine  green  stain.  The  lenses  were  graded  as  having
+  nuclear  sclerosis  with  1+  cortical  changes.  The  patient
as  negative  for  Hutchinson’s  sign.  All  other  ﬁndings  were
nremarkable.  Goldmann  tonometry  was  15  mmHg  OD  and
6  mmHg  OS.  Fundus  examination  was  also  unremarkable.
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FFigure  2A--I  Nine  diagnostic  action  ﬁelds  of  g
he  patient  was  diagnosed  with  HZO  of  the  left  side  and  was
ducated  to  continue  the  oral  acyclovir  800  mg  5  times  per
ay,  as  it  is  standard  protocol  for  HZO  reactivations,  along
ith  non-preserved  artiﬁcial  tears  4  times  a  day  OU,  and  to
eturn  for  follow-up  in  one  week  or  sooner  if  her  condition
orsened.
ollow-up  #1
he  patient  presented  one  week  later  with  complaints  of
uctuating  vision  and  tearing  OS  as  well  as  an  increased
tosis  of  the  left  eyelid.  The  patient  felt  her  vision  had
ecreased  since  the  previous  visit,  and  both  she  and  her
aughter  reported  excellent  compliance  with  oral  and  topi-
al  medication  therapy.  Her  entrance  acuities  with  spectacle
orrection  were  20/50+  OD  and  20/200  OS,  with  no  improve-
ent  with  pinhole  OU.  Pupil  examination  revealed  mild
nisocoria  with  the  left  pupil  being  slightly  larger  than  the
ight.  The  left  pupil  had  a  remarkably  minimal  response  to
ight  compared  to  the  right  and  also  showed  a  positive  APD
hen  a  binocular  indirect  ophthalmoscope  (BIO)  was  used  to
est  pupils.  The  patient’s  ocular  motility  was  normal  OD,  but
as  restricted  in  down  gaze  OS.  Gross  confrontation  visual
elds  were  full-to-ﬁnger-count  OD,  but  the  superior  visual
eld  defect  was  still  present  secondary  to  the  increased  lid
tosis  OS.  Slit  lamp  biomicroscopy  was  unremarkable  OD
xcept  for  moderate  nuclear  sclerosis  and  anterior  cortical
hanges  of  the  lens.  Biomicroscopy  OS  revealed  worsen-
ng  lid  swelling/ptosis  of  the  left  lid,  2--3+  conjunctival
njection,  3--4+  diffuse  corneal  punctate  epithelial  erosions
staining  with  both  lissamine  and  NaFl),  dark  and  quiet  ante-
ior  chamber,  clear  iris,  and  moderate  nuclear  sclerosis  and
nterior  cortical  changes  to  the  lens.  The  patient  was  dilated
ith  one  drop  of  1%  tropicamide  and  one  drop  of  2.5%
henylephrine  in  both  eyes.  Her  dilated  fundus  examination
as  performed  with  a  90D  lens,  and  with  BIO  in  conjunction
ith  a  20D  lens.  The  fundus  examination  was  unremarkable
D,  OS.
The  patient  was  diagnosed  with  a  partial  oculomotor
erve  (CN  III)  palsy  with  pupillary  involvement  OS,  secondary
o  HZO.  This  condition  is  also  referred  to  Herpes  Zoster
U
o
ademonstrating  restricted  EOMs  of  the  left  eye.
phthalmoplegia.  Due  to  the  cranial  nerve  and  pupil  involve-
ent,  she  was  referred  her  to  her  primary  care  physician
or  a  magnetic  resonance  angiogram  (MRA)  and  a  magnetic
esonance  imaging  (MRI)  to  rule  out  other  etiologies  of  cra-
ial  nerve  involvement  such  as  an  aneurysmal  compression
f  the  oculomotor  nerve  or  space-occupying  lesion.18 The
atient  was  to  continue  the  acyclovir  800  mg  5  times  per
ay  in  addition  to  non-preserved  artiﬁcial  tears  4  times  per
ay  and  was  to  return  for  follow-up  in  four  days  after  meet-
ng  her  primary  care  physician  to  review  the  results  of  her
maging.
ollow-up  #2
he  patient  presented  eleven  days  after  her  initial  visit  and
eported  undergoing  the  recommended  imaging  four  days
rior;  however,  the  results  were  not  scheduled  to  be  dis-
ussed  until  she  saw  her  primary  care  doctor  the  following
ay.  The  patient  complained  of  worsening  of  her  left  lid  pto-
is  as  well  as  diplopia  when  she  manually  lifted  her  left  lid  to
ee  (Fig.  2A--I).  Entering  acuities  remained  unchanged  from
he  previous  visit,  20/50  OD  and  20/200  OS  with  no  improve-
ent  with  pinhole  OU.  Her  pupils  were  anisocoric  (OS  larger)
nd  were  minimally  reactive  to  light  when  tested  with  a
IO  light  source.  External  examination  revealed  a  complete
eft  lid  ptosis.  The  patient’s  ocular  motility  now  revealed
 worsening/complete  cranial  nerve  III  palsy  OS.  Upon  fur-
her  questioning,  the  patient  reported  feeling  slightly  more
ll  than  previously  as  well  as  having  jaw  pain  and  scalp  ten-
erness  along  her  left  side.  Based  on  these  new  ﬁndings  and
omplaints,  she  was  sent  for  work-up  for  both  aneurysmal
ompression  of  the  third  cranial  nerve  and  giant  cell  arteri-
is  (GCA),  which  included  erythrocyte  sedimentation  rate
ESR)  and  C-reactive  protein  (CRP)  blood  work,  as  well  as
reatment  with  intravenous  steroids.
ollow-up  #3pon  discharge  from  the  hospital  the  patient  returned  to
ur  clinic  ﬁve  days  later  for  follow-up  (two  and  a half  weeks
fter  initial  presentation).  She  reported  feeling  better  and
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cFigure  3A--I  Nine  diagnostic  action  ﬁelds  of  gaze
noticed  slight  reduction  in  the  degree  of  her  left  ptosis.  The
patient  brought  her  emergency  visit  records  with  her  for
us  to  review  as  well.  Her  ESR  was  reported  at  21  and  the
CRP  was  <0.3,  which  is  within  normal  limits  for  her  age  and
suggested  GCA  was  not  the  cause  of  the  CN  III  palsy.  The
complete  blood  count  (CBC)  with  differential  proved  vir-
tually  normal  as  well.  The  patient’s  glucose  levels  ranged
from  168  to  225  mg/dl  while  on  the  intravenous  steroids.
The  patient’s  rapid  plasma  reagin  (RPR)  and  human  immune-
deﬁciency  virus  (HIV)  testing  were  negative.  However,  her
CD3  and  CD4  white  blood  cell  counts  were  low  indicating
a  certain  degree  of  immunosuppression.  Her  MRI/CT  scans
revealed  possible  enhancement  within  the  posterior  aspect
of  the  clivus,  which  was  suspicious  for  neoplastic  disease.
Thus,  the  hospital  physicians  scheduled  her  for  consultation
with  a  neurologist  secondary  to  her  history  of  breast  cancer.
Entering  acuities  at  this  visit  with  spectacle  correction
improved  to  20/40-2  OD  and  20/70  OS  with  no  improvement
with  pinhole  OD,  but  pinhole  improved  the  OS  to  20/60.
Gross  confrontation  visual  ﬁelds  were  full-to-ﬁnger-count
in  the  OD,  while  the  superior  visual  ﬁeld  defect  remained
secondary  to  the  lid  ptosis  OS.  Her  pupils  were  equal,  but
minimally  reactive  to  light  with  no  signs  of  APD  OU.  Her  ocu-
lar  motility  was  still  full  OD,  but  reduced  in  nasal,  inferior,
and  superior  gazes  OS.  Her  slit  lamp  examination  revealed
fully  resolved  corneal  issues  in  the  OS  and  otherwise  normal
anterior  segments  OU.  At  this  time,  pending  the  neurology
consult,  we  diagnosed  our  patient  with  HZO-induced  oph-
thalmoplegia  of  the  oculomotor/CN  III  nerve.  The  patient
was  directed  to  continue  her  oral  prednisone  and  follow-up
with  the  neurologist  for  ﬁndings  on  the  MRI  suggestive  of
possible  metastatic/neoplastic  disease.
Follow-ups  #4  and  5
Four  weeks  after  her  initial  presentation,  our  patient
reported  improvement  in  her  signs  and  symptoms.  Her
vision  was  back  to  pre-HZO  levels  of  20/50+  OU.  Her
confrontation  visual  ﬁelds  were  unchanged  from  previous
visits.  Her  ocular  motility  was  still  full  OD  and  restricted
OS,  but  deﬁnitely  improving  from  previous  visits.  Adnexal
examination  revealed  the  on-going  ptosis  OS,  but  the
r
o
s
aonstrating  improvement  in  EOMS  of  the  left  eye.
emaining  components  of  the  slit  lamp  examination  were
ormal  OU  with  the  exception  of  the  lenticular  changes
reviously  noted.  The  patient  was  released  and  asked  to
eturn  for  follow-up  after  her  neurology  consult  in  2  weeks.
ollow  up  #6
he  patient  returned  2  weeks  after  her  consultation
ith  the  neurologist  (seven  weeks  after  her  initial  pre-
entation).  The  neurologist  disagreed  with  the  possible
etastatic/neoplastic  disease  suggestions  of  the  emergency
hysicians  at  this  time,  but  wanted  to  monitor  the  patient
nd  repeat  the  MRI/CT  within  2--4  weeks  to  rule  this  out  and
onitor  for  changes.  The  neurologist  agreed  with  our  diag-
osis  of  oculomotor  nerve  palsy  most  likely  induced  by  the
ZO  outbreak.  At  this  visit,  the  patient’s  acuities  were  sta-
le  at  20/50+  OD  and  20/40+  OS.  Her  confrontation  visual
elds  were  full-to-ﬁnger  count  OU  and  her  pupils  were  equal
nd  reactive  to  light  without  an  APD  OU.  Her  ocular  motil-
ty  had  dramatically  improved,  yet  a  residual  ptosis  was
till  noted  OS,  though  it  had  improved  from  previous  visits
Fig.  3A--I).  Again,  her  slit  lamp  examination  was  within  nor-
al  limits  except  for  the  on-going  lenticular  changes  OU.
he  patient  was  told  to  keep  her  follow-up  appointment  with
er  neurologist  and  to  follow  up  with  us  in  4--6  weeks  to
onitor  for  anticipated  continuing  improvement  in  ocular
otilities.  Six  months  after  the  patient’s  initial  presenta-
ion,  her  ptosis  OS  had  resolved  and  she  regained  full  ocular
otilities.  She  is  currently  being  followed  every  six  months
nd  denies  ocular  problems  other  than  persistent  irritation
nd  tingling  around  her  left  eye.
iscussion
 cranial  nerve  III  palsy  results  in  adduction  and  vertical
cular  motility  deﬁcits  when  the  entire  nerve  is  implicated
nd  the  pupil  can  be  involved  as  the  pupillary  ﬁbers
ourse  through  cranial  nerve  III.7,8 Partial  palsies  can
esult  in  varying  degrees  of  involvement  of  directions
f  eye  movements.  Causes  are  varied  and  can  include
pace-occupying  lesions,  microvascular  infarctions,
neurysmal  compressions,  inﬂammation,  infections,
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nd  trauma.  Our  patient  initially  showed  anisocoria,  ptosis,
nd  restricted  down  gaze,  which  was  suggestive  of  a  partial
ranial  nerve  III  palsy.  Two  weeks  after  her  initial  presen-
ation,  she  showed  a  positive  APD,  increased  ptosis,  and
estricted  extraocular  motilities  suggestive  of  a  complete
N  III  palsy.  The  patient’s  ophthalmoplegia  and  ptosis
ontinued  after  the  resolution  of  her  cutaneous  lesions  and
eratitis.  Secondary  to  the  ophthalmoplegia,  the  patient
as  treated  with  intravenous  and  oral  steroids.  Over  the
ourse  of  six  months,  the  patient’s  signs  and  symptoms
mproved  markedly.  Six  months  after  the  onset  of  HZO,  she
ad  fully  recovered  from  the  ophthalmoplegia.
There  are  various  ocular  sequelae  with  HZO,  some  more
ommon  than  others.  Typically  in  HZO,  the  virus  causes  a
ermatitis/vesicular  rash  of  the  ophthalmic  branch  of  CN
.  Corneal  involvement  is  a  relatively  common  ocular  ﬁnd-
ng  and  can  lead  to  pseudo-dendritic  keratitis  which  can
esult  in  decreased  corneal  sensitivity,  neurotrophic  ulcers,
nd/or  decreased  vision  secondary  to  scarring.9 If  the  tip  of
he  nose  is  involved  with  the  vesicular  rash  this  is  termed
‘Hutchinson’s  sign’’  and  suggests  there  is  an  increased  risk
f  corneal/ocular  sequelae  secondary  to  nasociliary  nerve
nvolvement.2--4,19 One  of  the  most  common  complications  of
ny  HZ  outbreak  tends  to  be  post-herpetic  neuralgia  (PHN)
hich  can  cause  very  intense  episodes  of  pain  affecting  the
ame  areas  as  the  vesicular  rash.21
Overall,  ocular  complications  occur  in  50%  of  HZO  cases
nd  typically  fall  into  four  categories:  keratitis,  iritis,  mus-
le  palsies,  and  optic  neuritis.10 However,  HZO  uncommonly
esults  in  ophthalmoplegia.  In  one  study,  HZO  was  diag-
osed  in  10%  of  all  cases  of  HZ/shingles,  and  of  those  HZO
ases,  11--29%  went  on  to  develop  ophthalmoplegia  sec-
ndary  to  the  HZ  reactivation.10 This  means  only  1.1--2.9%
f  all  HZ/shingles  attacks  will  result  in  ophthalmoplegia
f  some  form,  demonstrating  how  rarely  a  case  like  ours
ccurs.  The  total  incidence  of  extraocular  muscle  palsy  fol-
owing  HZO  was  reported  by  Edgerton11 to  be  13%.  The
culomotor  nerve  (CN  III)  is  most  commonly  involved  (47%
f  the  time)  followed  by  the  abducens  nerve  (CN  VI)  (23%  of
he  time),  and  then  the  trochlear  nerve  (CN  IV)  (10%  of  the
ime).10--12 However,  there  have  been  documented  cases  of
omplete  ophthalmoplegia  (CN  III,  CN  IV,  and  CN  VI  palsies
ccurring  concurrently)  in  patients  following  an  outbreak  of
ZO,1,10 estimated  to  occur  20%  of  the  time  by  Edgerton.11
On  an  average,  HZO-induced  ophthalmoplegia  occurs
.5  days  after  the  onset  of  the  HZO  rash  in  75%  of  cases
ith  a  range  of  2--42  days.1 Our  patient’s  experience  is
n  accordance  with  this  estimate  as  she  ﬁrst  had  symp-
oms/signs  of  ophthalmoplegia  eight  days  after  the  onset
f  her  HZO.  Ophthalmoplegia  has  been  reported  to  occur
oncurrently  with  the  HZO  outbreak,  although  this  is  not
he  normal  presentation.1 Typically,  the  ophthalmoplegia  is
elf-limiting  and  results  in  complete  or  near-complete  res-
lution  on  its  own  in  4.4  months  on  an  average  in  65--76.5%
f  afﬂicted  individuals.1 However,  duration  varies  and  can
ange  from  2  weeks  to  1.5  years.1 In  some  patients,  residual
tosis  and/or  limited  ocular  motility  can  last  indeﬁnitely.20
Treatment  of  HZO  has  historically  been  with  oral  antivi-
al  agents  and  consists  of:  800  mg  of  acyclovir  5  times  a  day,
000  mg  of  valacyclovir  3  times  a  day,  or  500  mg  famciclovir
 times  a  day  for  7--10  days.4 However,  with  HZO-induced
cular  motor  palsies  the  treatment  is  controversial,  because
v
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he  overall  pathophysiology  of  ophthalmoplegia  associated
ith  HZO  is  unclear.  One  study  by  Theil  et  al.  looked  at  cra-
ial  nerve  nuclei  in  ﬁve  brains  to  determine  where  and  how
erpes  Simplex-1  virus,  VZV,  and  human  Herpes  Virus  type
 reactivate  to  cause  cranial  nerve  palsies  and  found  that
ZV  DNA  was  absent  in  all  the  brains  studied.  This  ﬁnding
uggests  that  the  triggering  of  the  nerve  palsies  is  in  the
ranial  nerve  nuclei  and  most  likely  occurs  further  down-
tream  in  the  nerve  conduction  pathway.13 This  would  be
onsistent  with  the  current  theory  of  reactivation  of  VZV
n  the  dorsal  root  ganglia.  In  general,  the  pathophysiology
f  HZO  is  believed  to  be  derived  from  different  compo-
ents:  viral  infection,  inﬂammatory  and  immune  reactions,
ascular  and  neural  inﬂammation,  and  tissue  scarring.6 As
 result  one  study  has  suggested  beneﬁts  of  concomitant
ral  and/or  intravenous  antiviral  and  oral  corticosteroid
se  to  decrease  both  viral  load  and  the  resulting  neu-
al  inﬂammation;  however,  conclusive  statistical  evidence
emains  elusive.1 Our  patient  was  treated  with  oral  steroids
fter  thorough  discussion  with  her  neurologist  to  prevent
cclusive  vasculitic  events.  The  patient’s  blood  sugar  was
onitored  regularly  as  elevated  blood  sugar  is  a  known
ide  effect  of  systemic  steroids  and  has  been  reported  to
e  a  common  cause  of  drug-induced  diabetes  mellitus.14
f  such  a  patient  experiences  unwanted  diplopia,  occlusion
r  prismatic  correction  might  be  beneﬁcial.  However,  for
ur  patient,  it  was  not  needed  due  to  the  ptosis  preventing
iplopia.
One  of  the  most  common  complications  of  any  herpes
oster  outbreak  is  PHN  and  treatment  success  remains  mod-
rate  at  best.  PHN  has  no  clear  deﬁnition  but  is  loosely
eﬁned  as  ‘‘clinically  signiﬁcant  pain  or  painful  abnormal
ensations  (allodynia  or  itch)  that  persist  3  months  or  more
fter  rash  onset’’.15,21 One  study  reported  the  presence  of
HN  in  15%  of  patients  being  treated  with  antiviral  drugs
ompared  to  35%  of  patients  not  being  treated  with  any
ntiviral  agents  at  all.5 PHN  is  much  more  common  in  elderly
opulations  than  in  younger  patients.  However,  PHN  does
ot  respond  very  well  to  treatment  and  can  lead  to  depres-
ion  as  the  PHN  can  drastically  affect  patients’  quality  of
ife.22 As  a  result,  tricyclic  antidepressants  and  selective
erotonin-reuptake  inhibitors  are  a mainstay  of  treatment
or  both  pain  and  depression.  Topical  agents  such  as  lido-
aine  patches  or  capsaicin  creams  have  been  shown  to  have
ome  efﬁcacy.9,16 Anticonvulsants  such  as  gabapentin  have
lso  been  shown  to  relieve  the  pain  of  PHN.9,16,20,21 Lastly,
SAIDs,  nonsteroidal  anti-inﬂammatory  drugs,  have  a  very
mall  effect  on  PHN  and  instead,  opioids  such  as  tramadol,
xycodone,  and  morphine  are  used  more  often.9,16 A  combi-
ation  of  many  pharmaceutical  agents  is  typically  employed
o  maximally  relieve  a  patient’s  pain  as  no  single  agent
rastically  reduces  the  effects  of  PHN.9,16 Since  our  patient
resented  with  symptoms  similar  to  those  described  in  GCA,
ut  had  normal  CRP  and  ESR  values,  we  can  assume  the
ain/discomfort  our  patient  experienced  was  most  likely
rom  PHN  affecting  CN  V  and  its  branches.  We  will  continue
o  monitor  our  patient  for  PHN,  along  with  her  neurologist,
nd  if  any  lingering  pain  occurs  we  plan  to  refer  her  to  either
he  neurologist  or  a  pain  specialist  for  PHN  therapy.A  newer  treatment  to  reduce  the  risk  of  HZ  is  via
accination  with  a  drug  known  as  Zostavax.  It  is  an
DA-approved,  live  attenuated  zoster  vaccine  used  to  boost
 Herpes  zoster  ophthalmicus-induced  oculomotor  nerve  palsy
the  cell-mediated  immunity  against  HZ  in  adults  ≥50  years
old.17 It  is  delivered  via  a  single  subcutaneous  injection.
This  drug  was  developed  based  on  the  Shingles  Prevention
Study  which  found  individuals  who  were  vaccinated  had  a
51%  lower  incidence  of  herpes  zoster,  a  67%  reduction  in
PHN,  a  61%  lower  burden  of  illness,  and  a  73%  reduction
in  the  number  of  cases  with  severe  and  long-lasting  pain
when  compared  to  placebo.17 Current  data  shows  contin-
ued  immunity  to  HZ  through  7  years  post-vaccination  with
ongoing  research  out  to  10  years  post-vaccination  in  place.
Due  to  the  success  of  this  vaccination,  medical  professionals
may  recommend  Zostavax  for  patients  older  than  50  years  of
age.  Vaccination  is  not  necessary  for  those  individuals  who
have  already  experienced  a  HZ  outbreak  as  that  event  par-
allels  exactly  what  the  vaccine  would  do  by  boosting  the
immune  system.  Re-activation  of  a  second  HZ  event  is  very
unlikely  for  this  same  reason.17 Thus,  Zostavax  would  not
necessarily  be  required  for  our  patient,  but  could  be  a  con-
sideration  which  can  be  discussed  on  a  patient-by-patient
basis  by  weighing  the  beneﬁts  and  risks  of  vaccination.
Conclusion
As  with  any  condition  that  can  have  many  causes,  timely
referral,  imaging,  and  blood  work  are  important  when  a
cranial  nerve  palsy  is  diagnosed,  to  rule  out  possible  life-
threatening  conditions.  In  our  case,  MRI/MRA  ruled  out
a  posterior  communicating  artery  aneurysm  and/or  space
occupying  lesion,  and  the  appropriate  blood  work  helped
us  to  rule  out  GCA.  Once  these  conditions  were  ruled  out
then  we  could  be  more  conﬁdent  that  our  patient’s  signs
and  symptoms  were  secondary  to  HZO-induced  ophthalmo-
plegia,  for  which  our  patient  ﬁts  the  typical  timeline,  signs,
and  symptoms.  The  jaw  pain  and  scalp  tenderness  that  our
patient  complained  of  (often  associated  with  GCA),  was
most  likely  related  to  PHN.  PHN  can  affect  the  branches
of  the  trigeminal  nerve  that  are  sensory  to  the  same  areas
(CN  V1,  V2,  V3)  and  is  the  most  common  complication
for  individuals  who  have  experienced  HZO  attacks.  Blood
work  revealed  lowered  CD3  and  CD4  counts  in  our  patient
signaling  a  certain  degree  of  immunosuppression,  which  was
most  likely  the  inciting  event  of  the  original  HZO  outbreak.
Immunosuppression  is  also  a  very  common  ﬁnding  in  indi-
viduals  suffering  from  HZ  outbreak.  This  case  demonstrates
the  relatively  uncommon  ophthalmoplegia  induced  by  HZO,
and  the  importance  of  co-management  between  health  care
practitioners.
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